Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2006 1
2008 1
2009 3
2010 4
2012 1
2013 1
2015 1
2017 1
2019 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, Chiang DY, Chuai S, Cogan SM, Collins SD, Dammassa E, Ebel N, Embry M, Green J, Kauffmann A, Kowal C, Leary RJ, Lehar J, Liang Y, Loo A, Lorenzana E, Robert McDonald E 3rd, McLaughlin ME, Merkin J, Meyer R, Naylor TL, Patawaran M, Reddy A, Röelli C, Ruddy DA, Salangsang F, Santacroce F, Singh AP, Tang Y, Tinetto W, Tobler S, Velazquez R, Venkatesan K, Von Arx F, Wang HQ, Wang Z, Wiesmann M, Wyss D, Xu F, Bitter H, Atadja P, Lees E, Hofmann F, Li E, Keen N, Cozens R, Jensen MR, Pryer NK, Williams JA, Sellers WR. Gao H, et al. Among authors: jensen mr. Nat Med. 2015 Nov;21(11):1318-25. doi: 10.1038/nm.3954. Epub 2015 Oct 19. Nat Med. 2015. PMID: 26479923
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer.
Auf der Maur P, Trefny MP, Baumann Z, Vulin M, Correia AL, Diepenbruck M, Kramer N, Volkmann K, Preca BT, Ramos P, Leroy C, Eichlisberger T, Buczak K, Zilli F, Okamoto R, Rad R, Jensen MR, Fritsch C, Zippelius A, Stadler MB, Bentires-Alj M. Auf der Maur P, et al. Among authors: jensen mr. Cell Rep Med. 2023 Apr 18;4(4):101002. doi: 10.1016/j.xcrm.2023.101002. Epub 2023 Apr 11. Cell Rep Med. 2023. PMID: 37044095 Free PMC article.
The NFIB-ERO1A axis promotes breast cancer metastatic colonization of disseminated tumour cells.
Zilli F, Marques Ramos P, Auf der Maur P, Jehanno C, Sethi A, Coissieux MM, Eichlisberger T, Sauteur L, Rouchon A, Bonapace L, Pinto Couto J, Rad R, Jensen MR, Banfi A, Stadler MB, Bentires-Alj M. Zilli F, et al. Among authors: jensen mr. EMBO Mol Med. 2021 Apr 9;13(4):e13162. doi: 10.15252/emmm.202013162. Epub 2021 Mar 10. EMBO Mol Med. 2021. PMID: 33751828 Free PMC article.
Targeting Hsp90 for the treatment of cancer.
Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J. Drysdale MJ, et al. Among authors: jensen mr. Curr Opin Drug Discov Devel. 2006 Jul;9(4):483-95. Curr Opin Drug Discov Devel. 2006. PMID: 16889231 Review.
OVCA1: emerging as a bona fide tumor suppressor.
Jensen MR, Helin K. Jensen MR, et al. Genes Dev. 2004 Feb 1;18(3):245-8. doi: 10.1101/gad.1184004. Genes Dev. 2004. PMID: 14871925 Free article. No abstract available.
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ. Garon EB, et al. Among authors: jensen mr. Mol Cancer Ther. 2013 Jun;12(6):890-900. doi: 10.1158/1535-7163.MCT-12-0998. Epub 2013 Mar 14. Mol Cancer Ther. 2013. PMID: 23493311 Free PMC article.
18 results